A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Oligometastasis
Oligorecurrences
Ovarian cancer
Personalized medicine
Stereotactic body radiotherapy
Stereotactic radiosurgery
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
20
04
2019
accepted:
23
08
2019
entrez:
12
2
2020
pubmed:
12
2
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Recent studies have reported improvement of outcomes (progression-free survival, overall survival, and prolongation of androgen deprivation treatment-free survival) with stereotactic body radiotherapy (SBRT) in non-small cell lung cancer and prostate cancer. The aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of SBRT in a very large, real-world data set of patients with metastatic, persistent, and recurrent ovarian cancer (MPR-OC). The endpoints of the study were the rate of complete response (CR) to SBRT and the 24-month actuarial local control (LC) rate on "per-lesion" basis. The secondary endpoints were acute and late toxicities and the 24-month actuarial late toxicity-free survival. Objective response rate (ORR) included CR and partial response (PR). Clinical benefit (CB) included ORR and stable disease (SD). Toxicity was evaluated by the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) and Common Terminology Criteria for Adverse Events (CTCAE) scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes. CR, PR, and SD were observed in 291 (65.2%), 106 (23.8%), and 33 (7.4%) lesions, giving a rate of CB of 96.4%. Patient aged ≤60 years, planning target volume (PTV) ≤18 cm This study confirms the activity and safety of SBRT in patients with MPR-OC and identifies clinical and treatment parameters able to predict CR and LC rate. This study aimed to define activity and safety of stereotactic body radiotherapy (SBRT) in a very large, real life data set of patients with metastatic, persistent, recurrent ovarian cancer (MPR-OC). Patient age <60 years, PTV <18 cm
Sections du résumé
BACKGROUND
Recent studies have reported improvement of outcomes (progression-free survival, overall survival, and prolongation of androgen deprivation treatment-free survival) with stereotactic body radiotherapy (SBRT) in non-small cell lung cancer and prostate cancer. The aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of SBRT in a very large, real-world data set of patients with metastatic, persistent, and recurrent ovarian cancer (MPR-OC).
MATERIALS AND METHODS
The endpoints of the study were the rate of complete response (CR) to SBRT and the 24-month actuarial local control (LC) rate on "per-lesion" basis. The secondary endpoints were acute and late toxicities and the 24-month actuarial late toxicity-free survival. Objective response rate (ORR) included CR and partial response (PR). Clinical benefit (CB) included ORR and stable disease (SD). Toxicity was evaluated by the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) and Common Terminology Criteria for Adverse Events (CTCAE) scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes.
RESULTS
CR, PR, and SD were observed in 291 (65.2%), 106 (23.8%), and 33 (7.4%) lesions, giving a rate of CB of 96.4%. Patient aged ≤60 years, planning target volume (PTV) ≤18 cm
CONCLUSIONS
This study confirms the activity and safety of SBRT in patients with MPR-OC and identifies clinical and treatment parameters able to predict CR and LC rate.
IMPLICATIONS FOR PRACTICE
This study aimed to define activity and safety of stereotactic body radiotherapy (SBRT) in a very large, real life data set of patients with metastatic, persistent, recurrent ovarian cancer (MPR-OC). Patient age <60 years, PTV <18 cm
Identifiants
pubmed: 32043791
doi: 10.1634/theoncologist.2019-0309
pmc: PMC7011643
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e311-e320Informations de copyright
© AlphaMed Press 2019.
Références
Oncologist. 2012;17(8):1100-7
pubmed: 22723509
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):650-660
pubmed: 29893277
Int J Gynecol Cancer. 2018 Oct;28(8):1507-1513
pubmed: 30036231
Pract Radiat Oncol. 2014 Jan-Feb;4(1):13-9
pubmed: 24621418
J Thorac Oncol. 2018 Oct;13(10):1549-1559
pubmed: 29959060
J Clin Oncol. 2009 Apr 1;27(10):1572-8
pubmed: 19255321
Radiother Oncol. 2017 Jul;124(1):11-17
pubmed: 28687397
JAMA Oncol. 2018 Jan 11;4(1):e173501
pubmed: 28973074
Front Oncol. 2017 Aug 21;7:177
pubmed: 28871275
J Clin Oncol. 2009 Apr 1;27(10):1579-84
pubmed: 19255320
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1026-32
pubmed: 15519771
Eur Urol Focus. 2017 Dec;3(6):538-544
pubmed: 28801240
Ann Oncol. 2017 Apr 1;28(4):727-732
pubmed: 27993805
Am J Clin Oncol. 2017 Apr;40(2):152-157
pubmed: 25171298
Cancer Treat Rev. 2015 Jun;41(6):503-10
pubmed: 25872878
Int J Mol Sci. 2018 Nov 28;19(12):
pubmed: 30487462
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Onco Targets Ther. 2017 Jul 26;10:3755-3772
pubmed: 28794640
Nat Med. 2018 Dec;24(12):1845-1851
pubmed: 30397353
Int J Gynecol Cancer. 2017 Feb;27(2):396-402
pubmed: 28114239
Br J Cancer. 2017 Jun 6;116(12):1520-1525
pubmed: 28449007
Br J Radiol. 2019 Feb;92(1094):20180422
pubmed: 30325662
Clin Cancer Res. 2015 Dec 1;21(23):5198-204
pubmed: 26626571
Cancer J. 2016 Jul-Aug;22(4):280-9
pubmed: 27441748
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Lancet Oncol. 2016 Dec;17(12):1672-1682
pubmed: 27789196
Front Oncol. 2012 Dec 05;2:181
pubmed: 23227452
Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56
pubmed: 29232464
Trends Immunol. 2018 Aug;39(8):644-655
pubmed: 30001871
Ann Oncol. 2019 May 1;30(5):721-732
pubmed: 30887020
Oncol Rep. 2014 Nov;32(5):2237-43
pubmed: 25175950
Med Oncol. 2018 Aug 4;35(9):121
pubmed: 30076479
Transl Lung Cancer Res. 2019 Feb;8(1):78-87
pubmed: 30788237